From professional translators, enterprises, web pages and freely available translation repositories.
diflubenzuron
diflubenzurons
Last Update: 2014-11-21
Usage Frequency: 8
Quality:
b2a (emamectin), b2f (teflubenzuron and diflubenzuron), b3e (mg and lmg)
b2a (emamektīns), b2f (teflubenzurons un diflubenzurons), b3e (mg un lmg)
Last Update: 2014-11-21
Usage Frequency: 1
Quality:
the sum total content of the following substances shall not exceed 2 ppm: diflubenzuron, triflumuron.
kopējais šādu vielu saturs nepārsniedz 2 ppm: diflubenzurons, triflumurons.
Last Update: 2014-11-21
Usage Frequency: 2
Quality:
it is therefore appropriate to include diflubenzuron for use in product-type 18 in annex i to that directive.
tāpēc ir lietderīgi diflubenzuronu iekļaut minētās direktīvas i pielikumā izmantošanai 18. veida produktos.
Last Update: 2014-11-09
Usage Frequency: 1
Quality:
the sum total content of the following substances shall not exceed 2ppm: diflubenzuron, triflumuron, dicyclanil.
Šādu vielu kopīgais saturs nepārsniedz 2 ppm: diflubenzurons, triflumurons, diciklanils.
Last Update: 2014-11-21
Usage Frequency: 1
Quality:
amending directive 98/8/ec of the european parliament and of the council to include diflubenzuron as an active substance in annex i thereto
ar ko groza eiropas parlamenta un padomes direktīvu 98/8/ek, lai iekļautu tās i pielikumā aktīvo vielu diflubenzuronu
Last Update: 2014-11-09
Usage Frequency: 1
Quality:
whereas novobiocin, betamethasone, spiramycin, diflubenzuron and enrofloxacin should be inserted into annex i to regulation (eec) no 2377/90;
tā kā novobiocīns, betametazons, spiramicīns, diflubenzurons un enrofloksacīns jāiekļauj regulas (eek) nr. 2377/90 i pielikumā;
amending annex i to council directive 91/414/eec as regards the specific provisions relating to the active substances clofentezine, diflubenzuron, lenacil, oxadiazon, picloram and pyriproxyfen
ar ko groza padomes direktīvas 91/414/eek i pielikumu attiecībā uz īpašajiem noteikumiem par aktīvajām vielām: klofentezīnu, diflubenzuronu, lenacilu, oksadiazonu, piklorāmu un piriproksifēnu
whereas, in order to allow for the completion of scientific studies, morantel, halofuginone, diflubenzuron, difloxacin and oxyclozanide should be inserted into annex iii to regulation (eec) no 2377/90;
tā kā, lai varētu pabeigt zinātniskos pētījumus, morantels, halofuginons, diflubenzurons, difloksacīns un oksiklozanīds jāiekļauj regulas (eek) nr. 2377/90 iii pielikumā;